Rosehip extract and wound healing: A review.

BACKGROUND: Each year, over 100 million patients are afflicted with new scars from medical procedures worldwide. Natural compounds have shown promise in the treatment of scars and skin disorders. Rosehip oil (RO), produced from the pressed fruit of the rosehip (Rosa canina L.) plant, is used in the pharmaceutical, cosmetic, and food industries. The use of this plant in the treatment of scars has yet to be reviewed. AIMS: This review aims to analyze the current findings on the use of RO in the treatment of postsurgical scars. METHODS: This literature search considered published journal articles (clinical trials or literature reviews). Studies were identified by searching electronic databases (PubMed and MEDLINE) and reference lists of respective articles. Additional articles were identified through Google Scholar. Only articles available in English were included in this review. RESULTS: There is a scarcity of high-quality studies assessing the therapeutic potential of RO. From the two human clinical trials using RO, there is some evidence to suggest its potential as an active ingredient in topical formulations for the treatment of wounds. Topical treatments containing RO extract may reduce the size and erythema of postsurgical scars through the polarization of macrophages and the inhibition of inflammatory cytokines. CONCLUSIONS: Some evidence suggests that RO may improve postsurgical scars. At present, there is insufficient evidence to recommend the use of RO for the treatment of wounds. Further investigation is required to establish its therapeutic effects on human skin and its potential use as an ingredient in topical formulations.

Effects of Daily Intake of Rosehip Extract on Low-Density Lipoprotein Cholesterol and Blood Glucose Levels: A Systematic Review.

This systematic review evaluates the effects of the daily intake of rosehip extract on low-density lipoprotein cholesterol (LDL-C) and blood glucose levels. It synthesizes findings from randomized clinical trials focusing on cardiovascular and metabolic health outcomes. The review includes studies employing various forms of rosehip supplementation, assessing primary outcomes such as LDL-C, HDL-C, total cholesterol, triglycerides, fasting blood glucose (FBG), and glycated hemoglobin (HbA1c). Secondary outcomes, such as body weight, BMI, and blood pressure, are also considered. The paper discusses the potential mechanisms of rosehip's action, including modulation of peroxisome proliferator-activated receptors and effects on various metabolic pathways. The results indicate mixed effects on lipid profiles and blood glucose levels, with some studies showing significant benefits. This review underscores the need for further research to confirm optimal dosages, treatment durations, and rosehip's efficacy in diverse populations, considering its favorable safety profile. The findings suggest the potential of rosehip extract as a complementary agent in managing cardiometabolic risk factors.